key: cord-0704701-8awzvbxz
authors: Chang, Kai‐Ming; Berlinrut, Ilan; Wallach, Frances R.
title: A case of severe COVID‐19 despite full vaccination with mRNA‐1273 SARS‐CoV‐2 vaccine (Moderna) in a kidney transplant recipient
date: 2021-08-16
journal: Transpl Infect Dis
DOI: 10.1111/tid.13710
sha: c71cacc3fe60ec00fa839a1945ae2170bf6920b2
doc_id: 704701
cord_uid: 8awzvbxz

nan

On examination, the patient appeared to be tachypneic. His vital signs revealed temperature 36.9 • C, blood pressure 97/55 mm Hg, pulse 100 beats per minute, respiratory rate 35 breaths per minute, the oxygen saturation 92% while breathing ambient air. He was started on Prednisone was held while he was receiving dexamethasone in the hospital. MMF 500 mg twice daily was also held, and it was resumed at 500 mg daily after discharge given his fragility. Tacrolimus extendedrelease tablet dosage was decreased from 16 mg to 10 mg daily in order to reduce immune suppression to target a level between 3.5 and 5.0 ng/ml. Inpatient daily tacrolimus levels ranged between 3.8 and 6.0 ng/ml. He received intravenous (IV) remdesivir for 4 days, but it was discontinued one day early due to acute kidney injury (serum creatine increased from baseline 1.25 to 1.96 mg/dl). On day 5 of hospitalization, the supplemental oxygen was discontinued while he was able to breathe comfortably on ambient air with oxygen satura- Markedly diminished generation of antigen-specific B cells, especially plasmablasts and memory B cells, can explain the low level of spike-antibody production by KTRs after vaccination. 8 Apart from the weak humoral response, KTRs also show impaired cellular response to mRNA vaccines. Spike-specific CD8+ T cells were minimally detectable in KTRs, accompanied by impairment of the interleukin-2 production and downregulation of other cytokine signaling pathways, while the CD4+ counterparts are comparable to healthy controls. 9 We hypothesized that COVID-19 infection boosted the vaccine-induced anti-spike antibody response in our patient but was not able to induce a natural antibody response to nucleocapsid protein.

Additional information is needed to recommend re-vaccination or additional doses of COVID-19 vaccines. The beneficial effect of a third dose of SARS-CoV-2 vaccine in SOT recipients has been described in a case series of 30 patients. 10 Of the six patients who had low-positive anti-spike antibody titers before the third dose, all developed high-positive antibody titers after receiving the third dose of vaccine. In contrast, of the 24 patients with negative antibody titers before the third dose, 16 (67%) remained negative. 10 Another study, involving 101 SOT recipients (including 78 KTRs), discovered that 26 of 59 (44%) seronegative patients became seropositive 4 weeks after receiving the third dose of BNT162b2 (Pfizer-BioNTech) vaccine. 11 Despite vaccination, immunocompromised patients need to continue precautions against SARS-CoV-2 as breakthrough infections remain a threat.

All the authors have contributed equally for preparation of the 

Occurrence of severe Covid-19 in vaccinated transplant patients

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States. Centers for Disease Control and Prevention

Antibody response to 2-Dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients

Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine

Reduced humoral response to mRNA SARS-Cov-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus

Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients

Impaired humoral and cellular immunity after SARS-CoV2 BNT162b2 (Tozinameran) prime-boost vaccination in kidney transplant recipients

Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients: a case series

Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients